For example, the high proportion of negative correlationsobserved in 4R-Tau samples (see Figure 2) could facilitate the development of a tool for differentialdiagnosis of neurodegenerative parkinsonism that would distinguishtauopathies (PSP and CBS) from synucleinopathies (DLB, PD, and MSA).55 Moreover, it may be possible to link observeddifferences in the concentrations of the panel metabolites to thediffering pathophysiologies of these conditions. The gene discussed is MAPT; the disease is Lewy body dementia.